Medidata presented two poster presentations at the ASCO meeting on May 29, 2026 [1], focusing on oncology protocol optimization and CAR-T efficacy [2].
These findings aim to streamline the complex process of clinical trial recruitment and improve the management of severe side effects associated with advanced cancer therapies. By leveraging AI-driven analytics, the research seeks to reduce the barriers that often delay the delivery of life-saving treatments to patients.
One presentation focuses on the use of AI to optimize oncology protocols, specifically targeting the improvement of enrollment for breast cancer trials [1]. The company said it intends to demonstrate how data-driven insights can identify more efficient pathways for patient recruitment, potentially shortening the time required to complete critical studies [1].
The second presentation examines the efficacy of tocilizumab in treating cytokine release syndrome (CRS) [2]. CRS is a systemic inflammatory response that can occur during CAR-T cell therapy, a type of immunotherapy that reprogrammes a patient's own T cells to attack cancer [2]. Medidata's research assesses therapeutic options to better manage this condition and improve patient safety during treatment [2].
Medidata, a Dassault Systèmes brand, operates as a provider of clinical trial solutions [1]. The company's presence at the ASCO meeting highlights a broader industry shift toward integrating artificial intelligence into the design and execution of oncology research [2]. The company said it is championing collaborative scientific advancement through these data-centric approaches [1].
The presentations were announced from New York [1]. While some secondary reports listed different dates and locations, the primary press releases confirm the May 29 event [1], [2], [3].
“Medidata presented two poster presentations at the ASCO meeting”
The integration of AI into clinical trial protocols represents a shift toward 'precision recruitment,' where data reduces the failure rate of trials caused by poor enrollment. Simultaneously, the focus on tocilizumab efficacy for CAR-T side effects indicates an industry-wide effort to make high-potency immunotherapies safer for wider patient populations.
